This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hongo, R. H. Articles by Scheinman, M. M. Search for Related Content PubMed PubMed Citation Articles by Hongo, R. H. Articles by Scheinman, M. M.

Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents

Richard H. Hongo, MD^*, Sakis Themistoclakis, MD, Antonio Raviele, MD, Aldo Bonso, MD, Antonio Rossillo, MD, Kathryn A. Glatter, MD, FACC, Yanfei Yang, MD^* and Melvin M. Scheinman, MD, FACC^*,*

^* University of California, San Francisco, San Francisco, California, USA
Umberto I Hospital, Mestre-Venice, Italy
University of California, Davis, Davis, CaliforniaUSA

View larger version (39K): [in a new window]   Figure 1 Assessment of QT interval during atrial arrhythmia and sinus rhythm. (A) The end of the QT interval (diamond) during atrial fibrillation is clarified by comparing it with the end of the QT interval in sinus rhythm (*) after conversion. (B) The end of the QT interval (diamond) during atrial flutter is clarified by comparing it with the end of the QT interval in sinus rhythm (*) after conversion.

View larger version (13K): [in a new window]   Figure 2 Time-to-event curves showing the estimated rate of ibutilide conversions during the 60-min observation period after ibutilide initiation, by arrhythmia type. AF = atrial fibrillation; AFL = atrial flutter.

View larger version (64K): [in a new window]   Figure 3 Change in overall corrected QT interval after ibutilide infusion.